Rezo Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Rezo Therapeutics's estimated annual revenue is currently $5.1M per year.
- Rezo Therapeutics's estimated revenue per employee is $155,000
Employee Data
- Rezo Therapeutics has 33 Employees.
- Rezo Therapeutics grew their employee count by 83% last year.
Rezo Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Rezo Therapeutics?
Rezo is a different kind of biopharma company. Our mission is to dramatically increase the success rate of drug development by building a disease-agnostic, fully-integrated, network biology platform that will redefine our understanding of human disease and ability to treat it. \n\nOur Founders and members of the Board are a group of esteemed, world-class scientists from the University of California, San Francisco: Nevan Krogan, Kevan Shokat, Sourav Bandyopadhyay, Natalia Jura, as well as renowned biotech executives George Scangos and Norbert Bischofberger. These leaders bring with them a strong track record of amazing discoveries and scientific breakthroughs, leading to very successful companies and many FDA approved drugs.
keywords:N/A
N/A
Total Funding
33
Number of Employees
$5.1M
Revenue (est)
83%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in San Francisco
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $4.1M | 33 | -44% | $71.7M |
#2 | $3.6M | 33 | -6% | $16M |
#3 | $3.7M | 33 | -15% | $2M |
#4 | $3.8M | 33 | -40% | N/A |
#5 | $3.8M | 33 | 27% | N/A |